Equilibrium and non-equilibrium charge-dependent quantification of endothelial cell hydrogel scaffolds

Arginine functionalization of hydrogels for heparin binding--a supramolecular approach to developing a pro-angiogenic biomaterial

Our aim was to synthesize a biomaterial that stimulates angiogenesis for tissue engineering applications by exploiting the ability of heparin to bind and release vascular endothelial growth factor (VEGF). The approach adopted involved modification of a hydrogel with positively charged peptides (oligolysine or oligoarginine) to achieve heparin binding. Precursor hydrogels were produced from copolymerization of N-vinyl pyrolidone, diethylene glycol bis allyl carbonate and acrylic acid (PNDA) and functionalized after activation of the carboxylic acid groups with trilysine or triarginine peptides (PNDKKK and PNDRRR). Both hydrogels were shown to bind and release bioactive VEGF165 with arginine-modified hydrogel outperforming the lysine-modified hydrogel. Cytocompatibility of the hydrogels was confirmed in vitro with primary human dermal fibroblasts and human dermal microvascular endothelial cells (HUDMECs). Proliferation of HUDMECs was stimulated by triarginine-functionalized hydrogels, and to a lesser extent by lysine functionalized hydrogels once loaded with heparin and VEGF. The data suggests that heparin-binding hydrogels provide a promising approach to a pro-angiogenic biomaterial.

Drug delivery applications for superporous hydrogels

INTRODUCTION

Considerable advances have been made to hydrogels with the development of faster swelling superporous hydrogels (SPHs). These new-generation hydrogels have large numbers of interconnected pores, giving them the capacity to absorb large amounts of water at an accelerated rate. This gives SPHs the ability to be used in a variety of novel drug delivery applications, such as gastric retention and peroral intestinal delivery of proteins and peptides.

AREAS COVERED

This review focuses on the applications of SPHs for drug transport and targeted drug therapies, as well as the characteristics and historical advancements made to SPH synthesis as it pertains to drug delivery. Manufacturing considerations and challenges that must be overcome are also discussed, such as scale-up, biocompatibility and safety.

EXPERT OPINION

Modern SPHs have high swelling and high mechanical strength making them suitable for many diverse pharmaceutical and biomedical applications. However, demonstrative preclinical animal studies still need to be confirmed in human trials, to further address safety issues and confirm therapeutic success when using SPHs as platforms for drug delivery. The focus of forthcoming applications of SPHs is likely to be in the area of oral site-specific delivery and regenerative medicine.